Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
PurposeNon-metastatic colorectal cancer patients with diabetes have poor overall survival thanthose without diabetes. However, the effect of hyperglycemia on survival after diagnosis ofmetastatic colorectal cancer (CRC) has not been assessed. Therefore, we assessed the impactof hyperglycemia on the survival and infection-related adverse events (AEs) in patientswith metastatic CRC. Materials and MethodsWe reviewed the records of 206 patients with newly diagnosed metastatic CRC who weretreated with palliative chemotherapy from March 2000 to December 2012 at ChungbukNational University Hospital. The mean glucose level of each patient was calculated usingall available glucose results. ResultsThe mean glucose levels ranged between 76.8 and 303.5 mg/dL, and patients were categorizedinto quartiles in accordance to their mean glucose level: group 1 (< 106.7 mg/dL),group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 mg/dL), and group 4 (> 142.6 mg/dL). The median overall survival for patients in groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and17.9 months, respectively; however, this difference was not statistically significant(p=0.643). Compared with patients in group 1, those in groups 2, 3, and 4 were at a higherrisk of infection-related AEs, according to a multivariate analysis (p=0.002). ConclusionHyperglycemia was not associated with shorter survival; however, it was associated withinfection-related AEs in patients with newly diagnosed metastatic CRC receiving palliativechemotherapy.
Abstract
PurposeNon-metastatic colorectal cancer patients with diabetes have poor overall survival thanthose without diabetes. However, the effect of hyperglycemia on survival after diagnosis ofmetastatic colorectal cancer (CRC) has not been assessed. Therefore, we assessed the impactof hyperglycemia on the survival and infection-related adverse events (AEs) in patientswith metastatic CRC. Materials and MethodsWe reviewed the records of 206 patients with newly diagnosed metastatic CRC who weretreated with palliative chemotherapy from March 2000 to December 2012 at ChungbukNational University Hospital. The mean glucose level of each patient was calculated usingall available glucose results. ResultsThe mean glucose levels ranged between 76.8 and 303.5 mg/dL, and patients were categorizedinto quartiles in accordance to their mean glucose level: group 1 (< 106.7 mg/dL),group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 mg/dL), and group 4 (> 142.6 mg/dL). The median overall survival for patients in groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and17.9 months, respectively; however, this difference was not statistically significant(p=0.643). Compared with patients in group 1, those in groups 2, 3, and 4 were at a higherrisk of infection-related AEs, according to a multivariate analysis (p=0.002). ConclusionHyperglycemia was not associated with shorter survival; however, it was associated withinfection-related AEs in patients with newly diagnosed metastatic CRC receiving palliativechemotherapy.
참고문헌 (25)
- 김신곤, "특집", 우리나라 당뇨병의 현황, 2008, pp.51(9), 791~798[DOI]
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010", Cancer Research and Treatment, 45(1), pp.1~14 (2013), 대한암학회[DOI]
- Giovannucci E, "Diabetes and cancer: a consensus report", CA Cancer J Clin, 60, pp.207~221 (2010)
- Jee SH, "Fasting serum glucose level and cancer risk in Korean men and women", JAMA, 293, pp.194~202 (2005)
- Larsson SC, "Diabetes mellitus and risk of colorectal cancer: a meta-analysis", J Natl Cancer Inst, 97, pp.1679~1687 (2005)
- Meyerhardt JA, "Impact of diabetes mellitus on outcomes in patients with colon cancer", J Clin Oncol, 21, pp.433~440 (2003)
- Dehal AN, "Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort", J Clin Oncol, 30, pp.53~59 (2012)
- Huang YC, "Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease", J Cancer Res Clin Oncol, 137, pp.211~220 (2011)
- van de Poll-Franse LV, "Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis", Int J Cancer, 120, pp.1986~1992 (2007)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Barone BB, "Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and metaanalysis", JAMA, 300, pp.2754~2764 (2008)
- Yancik R, "Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older", JAMA, 285, pp.885~892 (2001)
- Giovannucci E, "Metabolic syndrome, hyperinsulinemia, and colon cancer: a review", Am J Clin Nutr, 86, pp.s836~s842 (2007)
- Tran TT, "Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo", Endocrinology, 147, pp.1830~1837 (2006)
- Muller LM, "Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus", Clin Infect Dis, 41, pp.281~288 (2005)
- Turina M, "Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects", Crit Care Med, 33, pp.1624~1633 (2005)
- Jullumstro E, "Diabetes mellitus and outcomes of colorectal cancer", Acta Oncol, 48, pp.361~367 (2009)
- Polednak AP, "Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study", Cancer Detect Prev, 30, pp.466~472 (2006)
- 노금엽, "Effect of Diabetes Mellitus on Outcomes of Colorectal Cancer", Annals of Coloproctolgy, 26(6), pp.424~428 (2010), 대한대장항문학회
- Derr RL, "Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma", J Clin Oncol, 27, pp.1082~1086 (2009)
- Luo J, "Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients", Lung Cancer, 76, pp.242~247 (2012)
- Pickup JC, "Plasma interleukin- 6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes", Life Sci, 67, pp.291~300 (2000)
- Marhoffer W, "Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes", Diabetes Care, 15, pp.256~260 (1992)
- Sakowicz-Burkiewicz M, "Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes", Immunology, 118, pp.402~412 (2006)
- Peake PW, "Does non-enzymatic glycosylation affect complement function in diabetes?", Diabetes Res, 11, pp.109~114 (1989)